News

Patient perception of control affects satisfaction


 

Doctor consults with a cancer

patient and her father

Credit: Rhoda Baer

Feeling as though they play an active role in their treatment decisions increases satisfaction among cancer patients undergoing radiotherapy (RT), according to research published in Cancer.

In a study of more than 300 RT patients, those who were involved in their treatment decisions—or perceived they had some control over their treatment—were more satisfied than their peers.

On the other hand, patients who wanted control over their treatment but did not feel they had any were more likely than their peers to experience anxiety, depression, and fatigue.

“Our findings emphasize the value of patient-physician relationships and communication, specifically in radiation oncology, and their impact on patient experience in a way that hasn’t been shown before,” said study author Neha Vapiwala, MD, of the Perelman School of Medicine at the University of Pennsylvania.

Dr Vapiwala and her colleagues noted that past studies of shared decision-making (SDM)—in which patients and providers make healthcare decisions together, taking into account scientific evidence and patient preferences—have shown an association between patient satisfaction and quality of life.

However, none of these studies has evaluated the impact of SDM on patients undergoing RT. Often, radiation oncology is seen as a treatment avenue that is ultimately left to the physician to dictate. But there are tailored options, decisions, and discussions that can apply to individual patients.

With this in mind, the researchers conducted a survey of SDM in 305 patients undergoing RT. In all, 31% of patients said they experienced SDM, 32% perceived control in their treatment decisions, and 76% reported feeling very satisfied with their radiation treatment course overall.

Patient satisfaction was significantly higher among those who perceived SDM than among those who did not—84.4% and 71.4%, respectively (P<0.02).

And satisfaction was higher among patients who perceived control over their treatment than among those who did not—89.7% and 69.2%, respectively (P<0.001).

Patients who expressed a desire for control over their treatment decisions but did not perceive having any control were significantly more likely than their peers to experience symptoms tied to psychological distress.

Anxiety was reported in 44% and 20% of patients, respectively (P<0.02). Depression was reported in 44% and 15%, respectively (P<0.01). And fatigue was reported in 68% and 39.2%, respectively (P<0.01).

The researchers said one of this study’s strengths is the diverse group of patients enrolled. Ages ranged from 18 to 87 years, and a variety of ethnic/racial groups were represented. Patients had a range of cancers at all stages, and could participate in the study as long as they were well enough.

The team said the next step for this research is to determine both physician and patient barriers to SDM and identify methods to break down these barriers.

“As providers, it doesn’t matter what treatment you are offering, or how complicated it is, or how busy you may be,” Dr Vapiwala said. “It’s worth taking even a few minutes to talk to patients about seemingly minor decisions in which they can provide some input.”

“It’s not only critical in today’s healthcare setting, where both information and misinformation are rampant, but will very likely lead to the patient feeling positively about the encounter.”

Recommended Reading

‘Extremely exciting’ results from phase I trial of novel cancer metabolism agent
MDedge Hematology and Oncology
Minimal residual disease associated with overall survival in leukemia
MDedge Hematology and Oncology
New indices risk-stratify adults with cytogenetically normal acute myeloid leukemia
MDedge Hematology and Oncology
Dual kinase inhibitor targets heterogeneity in AML
MDedge Hematology and Oncology
ASCO releases guidelines for managing cancer survivors
MDedge Hematology and Oncology
Predicting risk of death in childhood cancer survivors
MDedge Hematology and Oncology
How NK cells kill abnormal blood cells
MDedge Hematology and Oncology
Compound is potent FLT3 inhibitor, team says
MDedge Hematology and Oncology
Molecule can increase Hb in anemic cancer patients
MDedge Hematology and Oncology
Enrollment stalled for CAR T-cell study
MDedge Hematology and Oncology